MedTrace Logo

Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

NCT00931281 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2010-10-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of multiple doses of an experimental hepatitis C virus (HCV) protease inhibitor with ritonavir in healthy volunteers.

Conditions

  • HCV Infection

Interventions

DRUG

ABT-450

capsules, QD or BID, 14 days, ascending doses

DRUG

ritonavir

capsules, QD or BID, 14 days, ascending doses

DRUG

Placebo for ABT-450

capsule, QD or BID, 14 days

DRUG

Placebo for ritonavir

capsule, QD or BID, 14 days

Sponsors & Collaborators

Principal Investigators

  • Isabelle A Gaultier, M.S., IBMH · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00931281 on ClinicalTrials.gov